Notably, we observed the administration of CMA decreased the levels of ALT and creatinine in all short‐term and longer‐term clinical trials and it decreased the level of uric acid in longer‐term AD and PD phase 2 clinical trials. This evidence concerns the gene GPT and Parkinson disease.